Latest News - Pharm Tech Europe
  • Subscribe / Renew
  • E-directory
  • Past Issues
  • About Us
  • Contact Us
  • Sign Up: e-Newsletter
 

ADVERTISEMENT

Sep 6, 2010

Latest News

The boom in the Middle East

01 June 2009

Until recently, the Middle East has accounted for only a fraction of global pharmaceutical sales, but this will soon change as the region's pharmaceutical market is estimated to exceed $18 billion by 2014.

News

01 June 2009

The latest growth forecast for the 2009 pharmaceutical market might have come as a shock to many, but there is still hope for the industry in the form of new product launches and potential blockbusters.

European initiative supports faster development of better medicines

29 May 2009

Out of 150 applications, 15 research projects aimed at bringing innovative medicines to market faster have been selected to receive 246 million euro from the European Commission (EC) and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Twice as many therapeutic peptides in the clinic

29 May 2009

Thanks to advances in synthesis, delivery and formulation, the number of therapeutic peptides entering clinical trials this decade is almost double the rate of the 1990s, and investment in new therapeutic peptide product development is expected to continue at a strong pace for the foreseeable future.

Xention strengthens team

29 May 2009

UK-based biopharmaceutical firm Xention has strengthened its team with the appointment of Dr Calum Graham as Director of Business Development.

EU & US approval process integration a necessity

29 May 2009

There is a pressing need to integrate the regulatory environments of the EU and the US, according to new analysis by Frost & Sullivan, which believes the diverse approval processes across different continents are negatively impacting drug launches.

Novartis gets exclusive option to acquire Elixir Pharmaceuticals

29 May 2009

Novartis (Switzerland) has signed an agreement that grants the company an exclusive option to acquire Elixir Pharmaceuticals (MA, USA) upon successful completion of a Phase IIa clinical study of Elixir?s lead oral ghrelin antagonist, which is now the subject of preclinical studies.

US orders H1N1 vaccines and vaccine antigen

29 May 2009

The US Department of Health and Human Services (HHS) this week placed an initial order with Sanofi Pasteur (France) for a vaccine to fight influenza A (H1N1) infection.

Who's the best in global biotech?

29 May 2009

A study has identified the innovative strength of more than 30 countries when it comes to biotechnology. Who came out on top?

Boost your marketing campaigns
Survey
Should a drug label state how the medicine compares with similar treatments?
Yes
No
Yes
53%
No
47%
View Results
Click here